mySURFACE
Surface target discovery - Transmembrane targets and target pairs
mySURFACE identifies and prioritizes individual transmembrane targets and target pairs by integrating large-scale cancer expression data with surface-protein prediction. Supporting evidence is consolidated in a hosted web application. It supports developers of antibodies, bispecifics, antibody-drug conjugates, and cell therapies who need differentiated, high-confidence surface targets or validated target combinations.
What mySURFACE delivers
Large-scale patient-cohort analyses have an average turnaround time of two to three months:
- Tumor specificity across bulk and single-cell expression and normal tissue
- Structural accessibility, including glycosylation and 3D structure
- Internalization capability and shedding assessment
- Co-expression and paired-target potential
- Published evidence consolidation
- Scores tailored to ADC, T-cell engager, and blocking formats
- Coverage analysis
- myADA: next-generation anti-drug antibody risk prediction
Compare surface targets in one view
Supporting evidence is consolidated in a hosted web application. Tumor specificity, structural accessibility, internalization, and paired-target potential sit together so biologics teams can compare individual transmembrane targets and combinations.
What is mySURFACE?
mySURFACE is myNEO's surface-target discovery platform for biologics. It identifies and prioritizes individual transmembrane targets and target pairs by integrating large-scale cancer expression data with surface-protein prediction. Supporting evidence is consolidated in a hosted web application at mysurface.myneotx.com (opens in a new tab).
Why is surface-target discovery a bottleneck for biologics?
Surface proteins are among the richest target classes in oncology but remain underexploited. Approved oncology biologics collectively address only a small number of distinct surface targets. As multispecific formats grow, developers need both new targets and validated target combinations.
What does mySURFACE evaluate for each candidate target?
mySURFACE assesses tumor specificity across bulk and single-cell expression and normal tissue, structural accessibility including glycosylation and 3D structure, internalization and shedding behavior, co-expression and paired-target potential, and published evidence. Scores are tailored to ADC, T-cell engager, and blocking formats.
Who is mySURFACE for?
mySURFACE supports developers of antibodies, bispecifics, antibody-drug conjugates, and cell therapies who need differentiated, high-confidence surface targets or validated target combinations with broad population coverage and evidence on accessibility, internalization, and normal-tissue expression.
What is the typical turnaround for mySURFACE?
Large-scale patient-cohort analyses with mySURFACE have an average turnaround time of two to three months. Project timing depends on scope and data readiness.